News
FEATURED STORIES
Regulators on both sides of the Atlantic are pushing for the withdrawal of the rare disease treatment that accounted for just 1% of Amgen’s 2025 revenue. Nevertheless, Amgen continues to defend the medicine, which was acquired in the $3.7 billion buyout of ChemoCentryx.
Psychedelics are gaining momentum in depression, with one treating physician predicting that the drug class could “wipe out the SSRIs” if safety and durability hold up.
Saol Therapeutics is the latest biotech to resubmit for approval of a drug rejected under former FDA Commissioner Marty Makary, following REGENXBIO and Replimune.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
Congressional letters sent to the CEOs of Eli Lilly, Pfizer, Merck, BMS and AbbVie this week voicing concerns about the pharmas’ clinical trials in China highlight an ongoing discrepancy in how government and industry think about the rise of the Asian country’s biotech industry.
THE LATEST
Chroma Medicine debuted Wednesday morning with $125 million in seed and Series A funding.
Earlier studies suggest a correlation between COVID-19 vaccines and menstrual changes. A new study says otherwise.
AcelRx Pharmaceuticals and Kala Pharmaceuticals both shared acquisition news on Monday. Here’s a closer look at each of the acquisition announcements.
After 32 years, gene therapy pioneer Guangping Gao, Ph.D., is finally seeing the fruits of the doctoral thesis research he started in 1989.
Scientists from Brigham and Women’s Hospital are ready to start a clinical trial that will evaluate the use of an intranasal vaccine to prevent Alzheimer’s disease.
Three companies have posted major developments in the field of heart disease therapy.
Pfizer’s oral antiviral treatment for COVID-19 is making its way through regulatory hurdles. The company is working with global manufacturers to ensure a steady supply of the medication.
It’s not unusual for biopharma companies to end the year with a restructuring that includes job cuts. Here are some of these companies.
Respiratory Syncytial Virus has been around for a very long period now. But there was no vaccine yet. But, here’s the first vaccine for RSV to shape the future.
Biogen announced that after 23 years with the company, Alfred W. Sandrock Jr. will retire on Dec. 31. Sandrock had his hand in the development of multiple treatments for neurological diseases.